Global Market for Huntington’s Disease Treatment Set for Rapid Growth

Selbyville, Delaware, Oct. 10, 2024 (GLOBE NEWSWIRE) — The Huntington's disease treatment market was assessed at USD 457.5 million in 2023, with a projected compound annual growth rate (CAGR) of 20.8% over the forecast period of 2024-2032. The market’s expansion is primarily driven by the increasing prevalence of Huntington’s disease and breakthroughs in medical research, according to Global Market Insights Inc.

Enhanced diagnostic methods and a greater awareness of the disease have resulted in the identification of more cases, thereby increasing the demand for effective treatment options. Recent advancements in genetic testing are enabling earlier and more accurate diagnostics, allowing for timely interventions. The availability of generic alternatives to key medications, such as tetrabenazine, has contributed to making treatments more affordable and accessible.

Furthermore, increased funding and investment from government entities, pharmaceutical companies, and private investors are expediting the discovery and development of new therapies. These factors collectively contribute to the significant expansion of the market, which categorizes drugs into types such as tetrabenazine, deutetrabenazine, and other medications. Tetrabenazine led the market in 2023, securing a 47.8% share, largely credited for its efficacy in managing chorea, a prominent symptom of Huntington’s disease.

The market also segments treatments into branded and generic categories. The branded segment was highly valued at USD 258 million in 2023. Branded medications are often supported by established efficacy, strong brand recognition, and endorsements in clinical guidelines, which reinforce their standing as standard treatments across various conditions.

In terms of geography, the North American market for Huntington’s disease treatments was valued at USD 183.9 million in 2023, with similar strong growth projections. Improved diagnostics and awareness campaigns have led to higher diagnosis rates and a greater demand for effective treatments in this region. The U.S. market alone was valued at USD 167.7 million in 2023, with expectations to reach USD 894.4 million by 2032, supported by its robust pharmaceutical research and development background.

Prominent companies in the Huntington’s disease treatment market include Bausch Health Companies Inc., CHEPLAPHARM Arzneimittel GmbH, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Neurocrine Biosciences, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories, LLC.